A comparative trial of large doses of ketoprofen and indomethacin in the treatment of rheumatoid arthritis

Af, El-Ghobarey; Ja, Rennie; Hadidi, T; Ha, Hamid; Mavrikakis, Myron

doi:10.1185/03007997609111999

Cited by 4 publications

(1 citation statement)

References 8 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparative Efficacy of Indomethacin16,[28][29][30][32][33][34][39][40][41] Superior functional improvement. b Reduced nighttime awakenings and morning stiffness.…”

mentioning

confidence: 99%

Role of Indomethacin in Acute Pain and Inflammation Management: A Review of the Literature

Nalamachu

Wortmann

2014

Postgraduate Medicine

View full text Add to dashboard Cite

Nonsteroidal anti-inflammatory drugs are a class of analgesics that includes traditional nonselective and selective cyclooxygenase-2 inhibitors that block the biosynthesis of prostaglandins and thromboxane. Indomethacin is a nonsteroidal anti-inflammatory drug with potent antipyretic, analgesic, and anti-inflammatory activity that has been effectively used in the management of mild-to-moderate pain since the mid-1960s. It is commonly prescribed for the relief of acute gouty arthritis pain, but has demonstrated efficacy in the treatment of various other painful conditions. Numerous comparative studies have affirmed the clinical utility of indomethacin relative to other widely used analgesics. This review provides an historic overview of indomethacin and its efficacy compared with other commonly used analgesics, and discusses new indomethacin drug products.

show abstract

“…Comparative Efficacy of Indomethacin16,[28][29][30][32][33][34][39][40][41] Superior functional improvement. b Reduced nighttime awakenings and morning stiffness.…”

mentioning

confidence: 99%

Role of Indomethacin in Acute Pain and Inflammation Management: A Review of the Literature

Nalamachu

Wortmann

2014

Postgraduate Medicine

View full text Add to dashboard Cite

show abstract

Anti-inflammatory analgesics and drugs used in rheumatism and gout

Prescott¹

1978

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Non-Steroidal Anti-Inflammatory Drugs and Gastroprotection with Proton Pump Inhibitors

Gigante¹,

Tagarro²

2012

Clinical Drug Investigation

View full text Add to dashboard Cite

Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed agents for rheumatic disorders such as osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Despite the known association between NSAID use and gastropathy, however, only around one-third of patients at risk of NSAID-induced gastrointestinal toxicity receive adequate gastroprotection, and as many as 44% of these patients are non-adherent. We review the co-prescription of proton pump inhibitors (PPIs) for the prevention of NSAID-induced gastropathy, with a particular focus on the first fixed-dose NSAID/PPI formulation: ketoprofen/omeprazole modified-release capsules. The ketoprofen/omeprazole fixed-dose combination is available in doses of 100 mg/20 mg, 150 mg/20 mg or 200 mg/20 mg as a single capsule for once-daily administration. Ketoprofen monotherapy has been shown to be generally equivalent to other NSAIDs when used in the treatment of OA. In RA, ketoprofen has demonstrated equivalent efficacy to diclofenac, indometacin, piroxicam, aceclofenac, phenylbutazone, naproxen and flurbiprofen. Studies comparing ketoprofen with ibuprofen and sulindac in patients with RA have, in general, favoured ketoprofen. Studies in AS have generally reported similar efficacy between ketoprofen and phenylbutazone and pirprofen. Prophylaxis with omeprazole is effective for the prevention of gastroduodenal ulcers, maintenance of remission and alleviation of dyspeptic symptoms in NSAID recipients. Omeprazole is well tolerated, and adverse events are generally gastrointestinal in nature. The fixed-dose combination of ketoprofen and omeprazole has demonstrated bioequivalence to the respective monotherapies. The incidence of digestive symptoms and the need for dose reduction was reported to be lower with the combination than with its components. Ketoprofen/omeprazole modified-release capsules are the first fixed-dose NSAID/PPI formulation to be approved. This formulation ensures compliance with the gastroprotective prophylaxis, as whenever the NSAID is taken, the PPI is co-administered. Additionally, the once-daily formulation has the potential to improve adherence to anti-inflammatory therapy.

show abstract

A comparative trial of large doses of ketoprofen and indomethacin in the treatment of rheumatoid arthritis

Cited by 4 publications

References 8 publications

Role of Indomethacin in Acute Pain and Inflammation Management: A Review of the Literature

Role of Indomethacin in Acute Pain and Inflammation Management: A Review of the Literature

Anti-inflammatory analgesics and drugs used in rheumatism and gout

Non-Steroidal Anti-Inflammatory Drugs and Gastroprotection with Proton Pump Inhibitors

Contact Info

Product

Resources

About